Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives

• US 20090252807A1
• Filed: 04/13/2006
• Published: 10/08/2009
• Est. Priority Date: 04/13/2005
• Status: Abandoned Application

• Current Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Original Assignee: Elan Pharma International Limited (Perrigo Company PLC)
• Inventors: Liversidge, Gary, Jenkins, Scott
• Application Number:
  US11/568,698
• Publication Number:
  US 20090252807A1
• Time in Patent Office: Days
• US Class Current: 424/491
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms.

Claims

1. A stable nanoparticulate prostaglandin derivative composition comprising:

(a) particles of a prostaglandin derivative; and

(b) associated with the surface thereof at least one surface stabilizer, wherein the prostaglandin derivative particles have an effective average particle size of less than about 2000 nm in diameter.

2. The composition of claim 1, wherein said prostaglandin derivative particle is selected from the group consisting of a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi amorphous phase, and mixtures thereof.

3. The composition of claim 1, wherein the composition is formulated for administration selected from the group consisting of oral tablets, capsules, sachets, solutions, dispersions and mixtures thereof.

4. The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

5. The composition of claim 1, wherein said prostaglandin derivative is present in an amount consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the prostaglandin derivative and at least one surface stabilizer, not including other excipients.

6. The composition of claim 1, wherein the at least one surface stabilizer is present in an amount of from about 0.5% to about 99.999% by weight, from about 5.0% to about 99.9% by weight, and from about 10% to about 99.5% by weight, based on the total combined dry weight of the prostaglandin derivative and at least one surface stabilizer, not including other excipients.

7. The composition of claim 1, wherein the surface stabilizer is selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, and an ionic surface stabilizer.

8. A composition according to claim 1 wherein said prostaglandin derivative is limaprost and which comprises:

(a) about 50 to about 500 g/kg limaprost;

(b) about 10 to about 70 g/kg hypromellose;

(c) about 1 to about 10 g/kg docusate sodium;

(d) about 100 to about 500 g/kg sucrose;

(e) about 1 to about 40 g/kg sodium lauryl sulfate;

(f) about 50 to about 400 g/kg lactose monohydrate;

(g) about 50 to about 300 g/kg silicified microcrystalline cellulose;

(h) about 20 to about 300 g/kg crospovidone; and

(i) about 0.5 to about 5 g/kg magnesium stearate.

9. The composition of claim 8, further comprising a coating agent.

10. A composition according to claim 1 wherein said prostaglandin derivative is limaprost and which comprises:

(a) about 100 to about 300 g/kg limaprost;

(b) about 30 to about 50 g/kg hypromellose;

(c) about 0.5 to about 10 g/kg docusate sodium;

(d) about 100 to about 300 g/kg sucrose;

(e) about 1 to about 30 g/kg sodium lauryl sulfate;

(f) about 100 to about 300 g/kg lactose monohydrate;

(g) about 50 to about 200 g/kg silicified microcrystalline cellulose;

(h) about 50 to about 200 g/kg crospovidone; and

(i) about 0.5 to about 5 g/kg magnesium stearate.

11. The composition of claim 10, further comprising a coating agent.

12. The composition of claim 1 formulated into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

13. The composition of claim 1, additionally comprising one or more active agents useful for the treatment of ischemic symptoms.

14. The composition of claim 1, wherein said one or more active agents is useful in the treatment of diseases selected from the group consisting of ulcer, pain and feeling of coldness associated with thromboangiitis obliterans, pain and numbness of lower legs, gait ability associated with acquired lumbar spinal stenosis, myocardial ischemia, stroke, erectile dysfunction, peripheral circulatory disorder, or decubitis.

24. A composition according to claim 1 which allows for the modified release of said prostaglandin derivative.

25. A composition according to claim 24 wherein said modified release is achieved using a modified release coating, a modified release matrix material, or both.

26. A composition according to claim 1 wherein said composition comprises immediate release particles.

15. A method of preparing a nanoparticulate prostaglandin derivative comprising contacting particles of said prostaglandin derivative with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate prostaglandin derivative composition having an effective average particle size of less than about 2000 nm in diameter.

16. The method of claim 15, wherein said contacting comprises:

(a) dissolving the prostaglandin derivative particles in a solvent;

(b) adding at least one surface stabilizer thereto;

(c) precipitating the solubilized prostaglandin derivative with the at least one stabilizer absorbed thereon by addition of a non-solvent.

17. A method of treatment of ischemic symptoms comprising the administration of an oral nanoparticulate prostaglandin derivative comprising particles of said prostaglandin derivative having at least one surface stabilizer associated with the surface thereof, wherein the particles have an effective particle size of less than about 2000 nm in diameter.

18. A controlled release composition comprising:

(A) a first population of prostaglandin derivative-containing particles which allows for the immediate or delayed immediate release of said prostaglandin derivative therefrom; and

(B) at least one subsequent population of prostaglandin-containing particles which allows for the modified release of said prostaglandin derivative therefrom;

said composition allowing the delivery of the prostaglandin derivative in a pulsatile or zero order manner.

19. The composition according to claim 18, wherein said modified release is achieved using a modified-release coating, a modified-release matrix material, or both.

20. The composition according to claim 18, wherein the amount of active ingredient contained in is from about 0.1 mg to about 1 g.

22. A method for the treatment of ischemic symptoms comprising administering a therapeutically effective amount of a composition according to claim 18.

21. The dosage form according to claim 59 wherein the composition is contained in a hard gelatin or soft gelatin capsule.

23. A composition comprising:

(A) prostaglandin derivative-containing particles which allow for the modified release of prostaglandin derivative therefrom; and

(B) a layer of prostaglandin derivative coated on top of said particles which allows for the immediate release of said prostaglandin derivative.

27. A pharmaceutical composition of an immunosuppressive agent comprising solid particles of the agent coated with one or more surface stabilizers, wherein the particles have an average effective particle size of from less than about 50 nm to less than about 2 microns.

28. The composition of claim 27, wherein the surface stabilizer is selected from the group consisting of:

anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, surface active biological modifiers, and combinations thereof.

29. The composition of claim 28, wherein the anionic surfactant is selected from the group consisting of:

sodium lauryl sulfate, sodium alginate, sodium carboxymethylcellulose, and calcium carboxymethylcellulose.

30. The composition of claim 28 wherein the cationic surfactant is selected from the group consisting of quarternary ammonium compounds, benzalkonium chloride, and lauryldimethylbenzylammonium chloride.

31. The composition of claim 27, wherein the surface stabilizer is a pegylated phospholipid.

32. The composition of claim 28, wherein the nonionic surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, cetyl alcohol, cetostearyl alcohol, methylcellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, polysaccharides, starches, starch derivatives, and polyvinylpyrrolidone.

33. The composition of claim 28, wherein the surface active biological modifier is selected from the group consisting of proteins, polysaccharides, and combinations thereof.

34. The composition of claim 33, wherein the polysaccharide is selected from the group consisting of starches and chitosans.

35. The composition of claim 33, wherein the protein is casein.

36. The composition of claim 27, further comprising a pH adjusting agent.

37. The composition of claim 36, wherein the pH adjusting agent is selected from the group consisting of succinic acid and citric acid.